NEW YORK (AP) -- Actavis said Tuesday that the Food and Drug Administration didn't approve its progestin-only contraceptive patch and wants more information on the drug.

The company said the FDA's questions are mostly regarding the drug's size and formulation. Actavis used one size and formulation in clinical trials and wants to market a different version.

Most birth control drugs use a combination of two female hormones, estrogen and progestin. The company's patch contains only progestin.


The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.